Literature DB >> 27520413

[Not Available].

K Herrlinger1, E F Stange2,3.   

Abstract

The etiology of inflammatory bowel diseases is still unknown. However, there seems to be a primary defect in mucosal barrier function resulting in a chronic inflammatory process. Both entities, Crohn's disease and ulcerative colitis show characteristic differences in clinical presentation and laboratory, radiological as well as endoscopical criteria. In some cases of the so called indeterminate colitis a clear distinction may not be possible. Therapy of inflammatory bowel disease aims for a suppression of the mucosal inflammation. Site, extent and especially the course of disease are crucial for the decision when and how to treat the patient. According to the patient's symptoms and disease history topical or systemic application of mesalazine or corticosteroids are used. In case of an intermittent course of disease treatment of the single flare should be started whereas in chronic active disease an immunosuppression with azathioprine, methotrexate or in therapy refractory cases infliximab is warranted.

Entities:  

Keywords:  Crohn's disease; Immunosuppression; Inflammatory bowel disease; Infliximab; Ulcerative colitis

Year:  2002        PMID: 27520413     DOI: 10.1007/s00108-003-1008-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  32 in total

Review 1.  Defensins and innate host defence of the gastrointestinal tract.

Authors:  C L Bevins; E Martin-Porter; T Ganz
Journal:  Gut       Date:  1999-12       Impact factor: 23.059

2.  A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.

Authors:  B G Feagan; R N Fedorak; E J Irvine; G Wild; L Sutherland; A H Steinhart; G R Greenberg; J Koval; C J Wong; M Hopkins; S B Hanauer; J W McDonald
Journal:  N Engl J Med       Date:  2000-06-01       Impact factor: 91.245

Review 3.  [The mucosal immune system. How clear is the pathophysiology?].

Authors:  M Holtmann; J Mudter; P R Galle; M F Neurath
Journal:  Internist (Berl)       Date:  2002-11       Impact factor: 0.743

Review 4.  [Laboratory values, endoscopy and new imaging. What is the status of diagnosis?].

Authors:  H Herfarth
Journal:  Internist (Berl)       Date:  2002-11       Impact factor: 0.743

5.  Response of refractory colitis to intravenous or oral tacrolimus (FK506).

Authors:  Klaus Fellermann; Zita Tanko; Klaus R Herrlinger; Thomas Witthoeft; Nils Homann; Andreas Bruening; Diether Ludwig; Eduard F Stange
Journal:  Inflamm Bowel Dis       Date:  2002-09       Impact factor: 5.325

6.  Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis.

Authors:  W Kruis; E Schütz; P Fric; B Fixa; G Judmaier; M Stolte
Journal:  Aliment Pharmacol Ther       Date:  1997-10       Impact factor: 8.171

7.  Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables.

Authors:  C Cammà; M Giunta; M Rosselli; M Cottone
Journal:  Gastroenterology       Date:  1997-11       Impact factor: 22.682

8.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

9.  Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease.

Authors:  Jan Wehkamp; Klaus Fellermann; Klaus R Herrlinger; Steffi Baxmann; Klaus Schmidt; Bettina Schwind; Michael Duchrow; Charlotte Wohlschläger; Alfred C Feller; Eduard F Stange
Journal:  Eur J Gastroenterol Hepatol       Date:  2002-07       Impact factor: 2.566

Review 10.  Crohn's disease: a defensin deficiency syndrome?

Authors:  Klaus Fellermann; Jan Wehkamp; Klaus R Herrlinger; Eduard F Stange
Journal:  Eur J Gastroenterol Hepatol       Date:  2003-06       Impact factor: 2.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.